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Concentration and avidity of antibodies to different
circumsporozoite epitopes correlate with RTS,S/
AS01E malaria vaccine efﬁcacy
Carlota Dobaño 1,2, Hèctor Sanz1, Hermann Sorgho3,17, David Dosoo 4,17, Maximilian Mpina5,6,7,17,
Itziar Ubillos 1, Ruth Aguilar 1, Tom Ford8, Núria Díez-Padrisa1, Nana Aba Williams1, Aintzane Ayestaran1,
Ousmane Traore3, Augusto J. Nhabomba2, Chenjerai Jairoce 2, John Waitumbi9,
Selidji Todagbe Agnandji 10,11, Simon Kariuki12, Salim Abdulla5, John J. Aponte1,2, Benjamin Mordmüller 11,
Kwaku Poku Asante4, Seth Owusu-Agyei4, Halidou Tinto3, Joseph J. Campo 1,2, Gemma Moncunill 1,2,
Ben Gyan4,13, Clarissa Valim14,15,16,18 & Claudia Daubenberger6,7,18
RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efﬁcacy in
African children and infants. In a cohort of 1028 subjects from one low (Bagomoyo) and two
high (Nanoro, Kintampo) malaria transmission sites, we analysed IgG plasma/serum con-
centration and avidity to CSP (NANP-repeat and C-terminal domains) after a 3-dose vac-
cination against time to clinical malaria events during 12-months. Here we report that RTS,S/
AS01E induces substantial increases in IgG levels from pre- to post-vaccination (p < 0.001),
higher in NANP than C-terminus (2855 vs 1297 proportional change between means), and
higher concentrations and avidities in children than infants (p < 0.001). Baseline CSP IgG
levels are elevated in malaria cases than controls (p < 0.001). Both, IgG magnitude to NANP
(hazard ratio [95% conﬁdence interval] 0.61 [0.48–0.76]) and avidity to C-terminus (0.07
[0.05–0.90]) post-vaccination are signiﬁcantly associated with vaccine efﬁcacy. IgG avidity
to the C-terminus emerges as a signiﬁcant contributor to RTS,S/AS01E-mediated protection.
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The RTS,S/AS01E is the most advanced malaria vaccine,consistently providing partial protection against clinicalmalaria in African children1–11, although the duration of
its moderate vaccine efﬁcacy is limited3. Vaccine efﬁcacy against
clinical malaria over a 12-month follow-up period estimated in
the African phase 3 randomised controlled trial was 55.8% in
children (5–17 months old at study start)1 and 31.3% in infants
(6–12 weeks old at study start)12. The vaccine is composed of
virus-like particles consisting of the hepatitis B virus surface
antigen (HBsAg) and the malarial target antigen, a fragment of
the Plasmodium falciparum circumsporozoite protein (CSP)
spanning the central region containing blocks of four amino acid
repeats (NANP) and the C-terminal (C-term) part and for-
mulated with AS01E adjuvant13. Previous paediatric phase
1/24,5,7,14,15 and the phase 316 clinical trials in Africa have shown
that RTS,S in its various adjuvant formulations induces high IgG
antibody titres to CSP NANP repeat that remain above naturally-
acquired levels for years17. Presently, it is unclear how the vaccine
protects against clinical malaria, and why and how the immune
mechanism of protection might be affected by age at ﬁrst
immunisation and malaria transmission intensity (MTI)18.
Thus far, vaccine immunogenicity measurements have focused
mainly on the NANP repeat as the immunodominant B cell
epitope16. Humoral responses to the subdominant C-term
domain have been evaluated in healthy malaria-naïve adults but
not in malaria-pre-exposed populations19. The C-term domain is
structurally conserved20 and B cell epitopes in this region have
not been characterized. Upon immunisation with P. falciparum
irradiated sporozoites, monoclonal antibodies against the C-term
are rarely induced in malaria naïve volunteers and thus far have
not demonstrated to mediate protection21. The C-term domain
contains a well-known promiscuous CD4+ T-cell epitope that is
conserved among all parasite isolates22.
Although the magnitude of anti-NANP repeat antibodies eli-
cited by RTS,S has been associated with vaccine efﬁcacy in some
studies, including the phase 3 trial16, others have shown that this
response is not associated with protection against clinical
malaria23,24. The biological function of IgG against the dominant
and subdominant CSP epitopes differs, which subsequently could
have an impact on protection. Analyses of RTS,S/AS01-induced
antibodies in phase 1/2a trials suggested that protected indivi-
duals had higher anti-NANP-speciﬁc IgG titres but of low
opsonisation activity. In contrast, antibodies targeting the C-term
in humans were associated with phagocytic activity19. Loss of C-
term speciﬁcity in the overall antibody response to CSP greatly
impaired protective efﬁcacy to P. berghei in mice25. The C-term
has been shown to take part in the initial entry of sporozoites into
hepatocytes26 and therefore, antibodies to this CSP fragment may
play a role in protection. There is recent evidence from ongoing
studies in our group of an association between post-vaccination
HBsAg IgG levels and malaria protection27 unreported in pre-
vious RTS,S ﬁeld trials. This might be explained partly by cor-
relation with CSP IgG levels16 thus further investigation is
required.
In addition to understand epitope ﬁne-speciﬁcity of RTS,S/
AS01E-induced IgG, it is essential to evaluate quality and quantity
of these IgG as a possible indicator of their biological function.
Studies conducted in prior phase 2 trials evaluated the avidity of
anti-NANP IgG responses in RTS,S vaccinees and found no
correlation between avidity post-third dose and vaccine
efﬁcacy28,29. Changes in NANP IgG avidity and concentration
following second and third doses, however, were associated with
reduction in clinical malaria risk. A recent phase 2a trial in
malaria naïve adults showed that a delayed fractional dose
boosting regimen increased antibody avidity and sustained higher
protection upon rechallenge30. Therefore, these outcomes merit
further evaluation as surrogate markers for RTS,S efﬁcacy. Prior
phase 2b trials suggested that IgG avidity was higher in children
with high malaria exposure compared to those with low malaria
exposure one-month post third vaccine dose28. The phase 3 trial
conducted under a wide range of MTI provides a unique
opportunity to address knowledge gaps of RTS,S immunogeni-
city, immune mechanisms mediating protection, and their
determinants.
This study aims to search for antibody correlates of RTS,S/
AS01E vaccine-induced protection against malaria by analysing
IgG concentrations and avidity to two CSP epitopes (NANP and
C-term), and IgG concentrations to HBsAg while considering the
effect of age at ﬁrst vaccination, MTI, and malaria IgG con-
centrations at baseline. We hypothesise that vaccine efﬁcacy also
relies on the contribution of anti-C-term domain binding IgG.
Here we show that the magnitude of IgG responses to CSP NANP
and C-term and HBsAg, and CSP antibody avidity, are sig-
niﬁcantly associated with RTS,S/AS01E vaccine efﬁcacy. Our data
show that IgG avidity to CSP C-term is important for RTS,S-
induced protection against clinical malaria.
Results
Study population. RTS,S/AS01E and comparator vaccinees
(Supplementary Fig. 1) were similar at baseline with regards to
demographic and clinical characteristics, except for sex (Table 1).
The majority of subjects (94%) completed the 12-month post-
vaccination follow-up time. The median time to drop out of the
study was 118 days ranging from 5 to 340 days. Most early ter-
minations were due to migration (33 subjects) or lost to follow-up
(26 subjects). A total of 669 malaria clinical events were recorded
during the follow-up time (24 in Bagamoyo, 241 in Kintampo and
404 in Nanoro). Of those, 48% were recorded in children and
66% ﬁrst events occurred within the ﬁrst six follow-up months.
Vaccine efﬁcacy within the ﬁrst 12 months of follow-up for ﬁrst
(40%; 95% conﬁdence interval [CI]= 29, 49%) and all (27%; 95%
CI= 20, 33%) malaria events decreased with time (p-Schonfeld
test= 0.04) and, as in the phase 3 RTS,S/AS01E trial, varied
across age groups (Supplementary Fig. 2). Vaccine efﬁcacy was
similar in the three sites: 40% in Nanoro, 43% in Bagamoyo, and
43% in Kintampo (p= 0.39, obtained in a Cox Proportional
Hazards model testing the interaction between site and
vaccination).
RTS,S/AS01E immunogenicity. RTS,S/AS01E vaccination
induced signiﬁcant increase of IgG concentrations (EU mL−1)
binding to CSP NANP and C-term at M3 compared to M0
(adjusted-P < 0.001 comparing logarithm of RTS,S:comparator
ratios estimated through mixed models) (Fig. 1a). Percentage of
responders was signiﬁcantly higher in RTS,S-vaccinees (98%
NANP, 99% C-term) when compared to comparators (9%
NANP, 12% C-term) (P < 0.001, Pearson Chi-squared test). The
concentration of CSP IgG in RTS,S compared to comparators at
post-vaccination (M3) was on average 6000 times higher for
NANP and 1600 times higher for C-term (P < 0.001 for both
ratios). IgG concentration (geometric mean [GM]) and avidity
index (AI) at M3 were 1652 and 0.39 for CSP NANP, respectively,
and 1241 and 0.10 for C-term. In spite of these differences, the
concentrations of IgGs to both CSP antigens were highly corre-
lated (Pearson-r= 0.93) (Fig. 1b). Correlations were lower but
still moderately high when analysing separately responses pre-
vaccination in both groups (Pearson-r= 0.48) and post-
vaccination in RTS,S/AS01E vaccinees (Pearson-r= 0.66), possi-
bly due to the narrower range of concentrations (Fig. 1b). There
was a weaker correlation (Pearson-r= 0.36) between NANP and
C-term AI (Fig. 1c).
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Factors affecting RTS,S/AS01E immunogenicity. Age at ﬁrst
vaccination and study site signiﬁcantly affected RTS,S/AS01E
immunogenicity (Fig. 2 and Supplementary Figs. 3 and 4; Sup-
plementary Table 2). The magnitude of the change in antibodies
from M0 to M3 was signiﬁcantly greater in children than infants
(Fig. 2a): in infants IgG concentrations post-RTS,S vaccination
increased from 4750 to 6300 while in children from 6470 to
25,353. Moreover, the changes from pre-vaccination to post-
vaccination in children were approximately 10 times larger for
NANP and 2.5 times larger for C-term responses than what was
observed in the infants cohort. At M0, infants had signiﬁcantly
higher IgG concentrations of CSP NANP and C-term compared
to children, most likely attributable to maternally-transferred
antibodies (Supplementary Fig. 3c). Higher baseline concentra-
tions of CSP IgG were associated with lower M3 antibody con-
centrations and lower changes from pre-RTS,S to post-RTS,S
vaccination (Supplementary Fig. 5). Percentage sero-positivity did
not differ signiﬁcantly between age groups (Supplementary
Table 1).
Volunteers from Nanoro (highest MTI) had higher concentra-
tions of anti-NANP and anti-C-term IgG than those from
Kintampo at baseline, and at both sites antibody levels were
higher than in Bagamoyo (lowest MTI) (Supplementary Fig. 3d).
The antibody increment between M0 and M3 was lesser in sites of
high MTI (Fig. 2b; p for all pairwise comparison of trajectories
between sites < 0.001). Among all other candidate predictors, only
weight-for-age Z-score (WAZ) had a signiﬁcant association with
immunogenicity (Supplementary Table 2). Sero-positivity in
Bagamoyo was lower than in the higher MTI sites and differences
were statistically signiﬁcant for NANP and borderline signiﬁcant
for C-term (Supplementary Table 1).
AI of CSP binding IgG was signiﬁcantly higher in children than
infants (Fig. 2c). Study site had a signiﬁcant effect on AIs
(Fig. 2d), and males had signiﬁcantly higher AI for C-term IgG
than females but no other sex effects were noted (Supplementary
Table 2).
RTS,S/AS01E vaccination induced IgG and malaria protection.
RTS,S vaccinees exhibiting M3 anti-NANP IgG concentrations
at the lower tertile had signiﬁcantly shorter median time to ﬁrst
clinical malaria event during 12 months of follow-up compared
to vaccinees with intermediate or highest anti-NANP
IgG concentrations (Fig. 3a). Differences in time to malaria
among RTS,S vaccinees across C-term IgG tertile concentra-
tions in the Kaplan–Meier analysis were not statistically sig-
niﬁcant (Fig. 3b). In contrast, among comparator vaccinees,
subjects with high tertiles of IgG NANP concentration at
M3 had shorter time to malaria (Supplementary Fig. 6).
Kaplan–Meier analysis of sero-positivity could not be done
since nearly all RTS,S vaccinees (>98%) had IgG concentrations
above the positivity cut-off and data was sparse in the negative
category.
Increased continuous concentrations of NANP and C-term
protected from ﬁrst event of clinical malaria after adjusting for
age and site, and results were comparable after adjusting for
baseline levels (Table 2). Speciﬁcally, 10 times increase in anti-
NANP IgG concentration was associated with a decrease in
malaria hazard by 33%. For C-term, a 11 times increase in IgG
concentration was associated with a decrease in malaria hazard by
51%. Although age and site were associated with the hazard of
ﬁrst clinical malaria, they did not modify the hazard ratio (HR) of
antibody concentration (p of interaction between 0.85 and 0.43).
In models including both antigens, NANP IgG concentrations
continued to be independently associated with ﬁrst clinical
malaria but not C-term (Table 2).
Table 1 Demographic and clinical characteristics of the whole study population
RTS,S/AS01E
(n= 706)
Comparator (n= 322) p value
Age at baseline, median (IQR) (weeks) 25 (7, 45) 27 (8, 46) 0.36
Age category, n (%), infants (vs children) 290 (41) 119 (37) 0.21
Site, n (%) 0.45
Bagamoyo 180 (25) 92 (29)
Kintampo 221 (31) 90 (28)
Nanoro 305 (43) 140 (43)
Sex, n (%), male 365 (52) 144 (45) 0.044
Weight, mean ± SD (kg) 6.5 ± 1.9 6.6 ± 1.9 0.56
Weight-for-age Z-score, mean ± SD −0.95 ± 1.21 −0.96 ± 1.23 0.94
Height, median (IQR) (cm) 65 (54, 70) 65 (55, 70) 0.56
Length/height-for-age Z-score, mean ± SD −1.32 ± 1.37 −1.32 ± 1.30 1.00
Number of clinical malaria episodes between pre- (M0) and post- (M3) vaccination,
n (%)
174 (25) 97 (30) 0.07
1 episode 157 (22) 79 (25)
2 or more episodes 17 (2) 18 (5)
Seasonality of transmission at the post-vaccination time point, n (%) 0.215
High 390 (55) 162 (50)
Low or no transmission 316 (45) 160 (50)
Anaemiaa, n (%) 0.25
No anaemia 142 (20) 71 (22)
Mild 180 (25) 67 (21)
Moderate or severe 384 (54) 184 (57)
Baseline haemoglobin level, mean ± SD (g dL−1) 9.74 ± 1.64 9.62 ± 1.74 0.28
Parasitaemia for subjects who had a ﬁrst clinical malaria episode between M3 + 14 days
and M15, Geometric mean ± SD
20,417 ± 18 22,387 ± 17 0.90
p-values were estimated using t-test where means and SD or geometric means and SD are reported; Wilcoxon Sum Rank test where medians and IQR are reported; Pearson Chi-square or Fisher exact
test when proportions are reported
IQR interquartile range, SD standard deviation, kg kilograms, M month
aBased on the World Health Organization cut off reference values: no anaemia ≥110 g L−1, mild anaemia 100–109 g L−1, moderate or severe anaemia <99 g L−1, http://www.who.int/vmnis/indicators/
haemoglobin.pdf?ua=1
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Survival analysis of AI at M3 showed that RTS,S vaccinees with
NANP and C-term values at the lower tertile had signiﬁcantly
shorter median time to ﬁrst clinical malaria event during
12 months of follow-up than vaccinees with intermediate or
highest AI values (Fig. 4). In contrast to IgG concentrations,
associations between AI and malaria protection appeared to be
consistent for NANP and C-term.
Increased continuous AI of both NANP and C-term IgGs was
positively correlated with protection from ﬁrst clinical malaria
event in RTS,S vaccinees (Table 3). Joint analyses of IgG
concentration and AI suggest that responses to the two antigens
may have distinct behaviours. In those models, C-term AI
continued to be independently associated with ﬁrst clinical
malaria but not NANP AI. After adjusting for anti-NANP IgG
concentration, the correlation of C-term AI with malaria
protection continued to be signiﬁcant (Table 3) suggesting that
the association was independent of the correlation between anti-
C-term and anti-NANP responses (Fig. 1b, c). The scatterplots in
the Supplementary Fig. 7 suggest that correlation between IgG and
AI for C-term is indeed weaker than for NANP. Moreover, for C-
term, the association between AI and time to ﬁrst clinical malaria
varied according to IgG concentration. In subjects with low C-
term IgG, low AI resulted in shorter median time for clinical
malaria (Supplementary Fig. 8). The differences between time to
malaria and AI levels decreased in subjects with intermediate C-
term IgG concentration. For subjects with high IgG concentration,
high C-term AI protected from clinical malaria by delaying the
ﬁrst clinical event. NANP, contrasting with C-term, had
comparable effect of AI on clinical malaria across AI levels for
subjects with different levels of NANP IgG concentration,
suggesting that AI played a lessen role in protection from malaria.
When analysing repeated clinical malaria events, the associa-
tion between continuous IgG NANP and C-term concentrations
varied over time, as expected given prior evidence that vaccine
efﬁcacy could wane during the 3–6 months post vaccination
(Fig. 5a, b). Increased IgG concentration statistically signiﬁcantly
protected from recurrent clinical malaria for the ﬁrst 3 months
post-vaccination with the HR varying from 0.015 to 0.032. After
that, the HR became not statistically signiﬁcant. From approxi-
mately 6.5 months until the end of follow-up at 12 months post-
vaccination, the HR was still not statistically signiﬁcant but
ranged from 1 to 1.6, suggesting that lgG to NANP and C-term
did not have any effect on the hazard of malaria or marginally
increased the risk, perhaps due to unmeasured confounding with
exposure to malaria. In contrast, AI in absence of adjustments for
IgG concentration was constant and protective of recurrent
clinical malaria events for both NANP and C-term (Fig. 5c, d).
Conclusions were comparable after adjustments for age and study
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Fig. 1 Effect of RTS,S/AS01E vaccination on anti-CSP IgG responses. a Ratios of mean concentrations (log10[EU mL−1]) between RTS,S/AS01E and
comparators, before (month [M]0) and after (M3) vaccination, adjusted by site, with adjusted-p-values obtained in linear regression
coefﬁcients comparing for signiﬁcance of logarithm of ratios estimated through mixed models. Error bars represent 95% conﬁdence intervals (CI)
estimated ﬁtting the mixed model. b Correlations between CSP NANP and C-terminus (C-term) IgG concentrations. Regression lines with scatterplots
show the association among: (i) all subjects pre-vaccination and post-vaccination in a dashed orange line (r= 0.93; 95% CI= 0.93, 0.94); (ii) comparator
vaccinees pre-vaccination (black circles) and post-vaccination (black triangles) and RTS,S/AS01E pre-vaccination (green circles) (r= 0.48; 95% CI= 0.42,
0.54) in a solid black line; (iii) RTS,S/AS01E post-vaccination (green triangles; r= 0.66; 95% CI= 0.62, 0.70) in a solid green colour line. c Correlations
between CSP NANP and C-term IgG avidity index (AI). Only samples with IgG concentration above the assay lower limit of quantiﬁcation (LLOQ)
(NANP >1.43 EU mL−1 and C-term > 2.79 EU mL−1) are shown, and those were mostly referring to post-vaccination RTS,S/AS01E vaccinees (r= 0.36;
95% CI= 0.29, 0.42). The strength of associations represented by the slope of each regression line is also shown (all slopes with p value < 0.05, obtained
in linear regression coefﬁcient of the slope, i.e. a t-test of the slope )
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Fig. 2 Effect of age cohort and site on RTS,S/AS01E immunogenicity. Comparison of the impact of RTS,S/AS01E vaccination on anti-CSP responses across
age cohorts (a IgG; c AI) and sites (b IgG; d AI). a Estimates of changes over time of infants (aged 6–12 weeks at vaccination) and children (aged
5–17 weeks at vaccination) and statistical signiﬁcance of those were estimated through multivariate mixed models. Trajectories of NANP of infants and
children were signiﬁcantly different within vaccination group (all p values < 0.001). b Estimates of changes over time in each study site. Trajectories were
statistically signiﬁcantly different across sites (p adjusted for multiple testing for all pairwise comparisons < 0.001). Post-vaccination AI is compared across
age cohorts (c) and sites (d) through t-tests and ANOVA, respectively. Boxplots illustrate the medians and the 25th and 75th quartiles, diamonds show the
geometric mean, whiskers display the 1.5 interquartile ranges, and dots the outliers. M0: pre-vaccination, M3: post-vaccination
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site, although both factors were associated with recurrent clinical
malaria events.
Finally, we found that RTS,S vaccinees (Fig. 6a) (but not
comparator vaccinees, Supplementary Fig. 6) in the low tertile of
anti-HBsAg IgG concentration had signiﬁcantly shorter median
time to ﬁrst clinical malaria event than those with higher
concentrations. In analysis of continuous anti-HBsAg IgG
adjusted by age cohort and site, the protective association of
anti-HBsAg IgG concentrations with ﬁrst (Fig. 6b) and recurrent
(Fig. 6c) clinical malaria events was signiﬁcant for the ﬁrst six
months of follow-up. After adjusting for anti-NANP IgG
concentration, the correlation with protection from ﬁrst (Fig. 6b)
and recurrent malaria events (Fig. 6d) of anti-HBsAg IgG
concentration continued to be strong suggesting that the
association was independent of the correlation between anti-
HBsAg IgG and anti-NANP IgG concentrations.
Discussion
We demonstrate here that anti-CSP IgG concentrations and
avidity are correlates of RTS,S induced-protection and that these
are affected by age, site and baseline. Our ﬁndings conﬁrm data
from previous phase 3 analyses showing that RTS,S/AS01E
vaccination elicits a potent IgG response to the immunodominant
NANP and at higher concentrations in children than infants3,16.
Importantly, our study was designed and powered to detect
immune correlates of protection and to assess the role of age at
ﬁrst vaccination and MTI on immunogenicity. We conﬁrmed that
anti-NANP CSP antibodies contribute to protection16 against
ﬁrst or recurrent malaria events during 12-months post-immu-
nisation, adjusted by age, site, and also baseline antibodies. This is
relevant because correlation between CSP IgG titres and protec-
tion against malaria has not always been consistent in previous
phase 2b trials, as this association has been dependent on age
and/or malaria endpoint (infection vs disease), among other
factors4,5,7,14,17.
We expanded the analysis of CSP epitope targets by including
the C-term domain. We demonstrated that RTS,S/AS01E vacci-
nation induces IgG to this subdominant region and that despite
their lower concentrations compared to anti-NANP, these anti-
bodies were also associated with vaccine efﬁcacy.
In addition, we assessed not only the magnitude but also the
quality of vaccine-induced antibodies and their relevance to
protection. Two ﬁeld studies of RTS,S evaluated the avidity of
anti-NANP CSP IgG in African children and found no
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p-value difference across strata < 0.001
p-value difference across strata = 0.20
Median survival time (days):
High: 234 (205, 331)
Medium: 289 (230, ∞)
Low: 163 (138, 192)
Number of subjects:
High: 218 children/19 infants
Medium: 141 children/88 infants
Low: 48 children/182 infant
Median survival time (days):
High: 209 (190, 234)
Medium: 225 (185, 325)
Low: 208 (174, 268)
Number of subjects:
High: 155 children/84 infants
Medium: 143 children/88 infants
Low: 114 children/118 infants
Fig. 3 Effect of CSP antibody concentration on protection against the ﬁrst malaria episode. Kaplan–Meier estimates of time to the ﬁrst clinical malaria
episode during the 12-month follow-up period after the third vaccine dose by the three tertiles (high in grey; medium in blue; low in yellow) of IgG
concentrations (EU mL−1) to NANP (a) and to C-terminus (b) at month 3 in RTS,S vaccinees. The median survival time (days), i.e., time after which 50% of
the cohort has not yet had an event, is shown for each antibody tertile with the corresponding 95% conﬁdence intervals. p-values assessing differences in
the distribution of survival time across the three strata in each of the subgroups were estimated through the Log-rank test. The number of subjects in each
tertile are also indicated next to the plots, stratiﬁed by age group
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correlation between M3 avidity and vaccine efﬁcacy28,29. A
challenge study in naïve adults showed an association between
higher avidity and protection30. Here, we showed that malaria-
exposed children generated vaccine-induced antibodies with
higher AI than infants. This suggests that, in addition to high
concentrations, afﬁnity matured antibodies that probably exert
better biological functions confer protection against malaria.
When multivariable Cox models were adjusted for the other CSP
construct and/or the other metric (concentration or AI), the
relationship between IgG recognising NANP and malaria pro-
tection was different from that of IgG to C-term. Notably, the
association between C-term AI and malaria protection remained
signiﬁcant even after adjusting for NANP IgG concentration.
Taken together, data indicated that for the NANP region, anti-
body concentration might be more important in protection than
avidity, whereas for the C-term region, the opposite was observed.
Indeed, exploratory data analyses pointed to different response
patterns in concentrations vs avidities for C-term and NANP.
Therefore, the association of one metric with malaria risk was not
necessarily confounded by the other metric/antigen.
The magnitude of the HBsAg IgG response was also correlated
with time to malaria event, in the ﬁrst six months after vacci-
nation. This ﬁnding could either reﬂect vaccine take as HBsAg is
a component of RTS,S/AS0E, thus related to the correlation of
anti-CSP and anti-HBsAg IgG titers (rho≅ 0.7 in this and other
studies)16,27, or might also reﬂect an impact of the HBsAg antigen
on the afﬁnity maturation of CSP-speciﬁc antibodies resembling
the carbohydrate-based conjugate vaccines. As the biological
relevance of such association remains unclear, mechanisms and
implications for potential interactions between HBsAg and CSP
speciﬁc responses will be the focus of future studies.
We conﬁrmed that RTS,S/AS01E immunogenicity was higher
in the children than in infants. Previous correlates analyses within
the phase 3 trial found an association between high tertile M3
NANP IgG titres and vaccine efﬁcacy over the long term follow-
up (M30) in infants but not in children3. Here, in the analysis of
factors affecting the association between antibody concentrations
and malaria events, infants had an increased risk compared to
children to acquire malaria. The higher antibody concentrations
and AI in children compared to infants could partially explain
why RTS,S is more efﬁcacious in older ages1–3. The nature and
kinetics of IgG afﬁnity maturation to dominant (NANP) vs
subdominant (C-term) epitopes could be different, and this may
also impact the age-related pattern of association between anti-
bodies and malaria protection.
Furthermore, we assessed if the concentration of baseline
antibodies to RTS,S antigens affected the outcome of vaccination
at the individual level. Presence of CSP antibodies at time of ﬁrst
vaccination due to maternally-transferred antibodies during the
ﬁrst months of life and/or to malaria exposure could impact RTS,
S immunogenicity, and this may affect infants and children dif-
ferentially. Indeed, baseline concentrations of anti-CSP IgG were
higher in subjects from Nanoro than those in Kintampo or
Bagamoyo. We have shown previously that baseline levels of CSP
IgG in infants aged less than 10 months (thus presumably
transferred in utero from the mother) correlate positively and
signiﬁcantly with baseline levels of IgG to P. falciparum antigens
—therefore representing markers of malaria exposure27. In chil-
dren older than 10 months, baseline CSP IgGs would likely be
acquired upon infection and increase with age and MTI. A prior
analysis of the effect of anti-NANP CSP IgG within the phase 3
trial reported that pre-vaccination titres were associated with
lower RTS,S immunogenicity in infants and higher immuno-
genicity in children16. We conﬁrm a signiﬁcant correlation
between higher M0 and lower M3 CSP NANP IgG concentrations
and expand this for C-term IgG. These associations were sig-
niﬁcant when infants and children were analysed together, but
they were more prominent for NANP IgGs and for infants.
Subjects who developed malaria during the 12-month follow-up
period had higher concentrations of IgG CSP at baseline and
induced lower concentrations of IgG at M3, thus the increments
from M0 to M3 in the non-protected subjects were lower than in
protected volunteers. Thus, naturally-acquired CSP antibodies (at
M0, and at M3 in comparator vaccinees) were markers of
exposure, while RTS,S/AS01E-induced CSP (M3) are markers of
protection. Malaria episodes during the vaccination period were
also associated with increased malaria risk post-vaccination. As
malaria exposure may affect the phenotype and function of
Table 2 IgG antibody concentrations to CSP in relation to risk of clinical malaria
All subjects at M3 Subjects at M3 with matched M0 sample available
NANP C-term NANP+
C−term
C-term+
NANP
NANP NANPa C-term C-terma
n subjects 696 702 694 694 522 522 528 528
Concentration
CSP IgG M3
0.69
(0.60, 0.78)
0.77
(0.64, 0.92)
0.61
(0.48, 0.76)
1.21
(0.92, 1.59)
0.71
(0.60, 0.83)
0.73
(0.62, 0.86)
0.86
(0.68, 1.01)
0.84
(0.7, 1.06
Concentration
CSP IgG M0
– – – – – 1.24
(1.03, 1.48)
– 1.30
(1.05, 1.62)
Site
Bagamoyo Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
Kintampo 25.2
(13., 5 47.0)
19.9
(11.2, 35.6)
24.8
(13.3, 46.3)
24.8
(13.3, 46.3)
20.3
(10.7, 38.4)
19.7
(10.4, 37.3)
16.3
(9.1, 29.6)
15.9
(8.8, 28.8)
Nanoro 42.8
(22.9, 79.9)
33.6
(18.8, 60.1)
41.0
(21.9, 76.7)
41.0
(21.9, 76.7)
26.3
(13.1, 52.8)
24.1
(11.9, 48.8)
21.3
(11.1, 41.2)
19.9
(10.27, 38.6)
Age cohort
5–17 months Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
6–12 weeks 0.73
(0.59, 0.91)
0.92
(0.76, 1.13)
0.70
(0.55, 0.88)
0.70
(0.55, 0.88)
0.98
(0.71, 1.36)
0.82
(0.58, 1.17)
1.17
(0.86, 1.61)
1.15
(0.84, 1.57)
Hazard ratios (95% conﬁdence intervals) for the ﬁrst clinical malaria episode during the 12-month follow-up period after the third vaccine dose in relation to concentrations of IgG antibody against CSP
peptides at month (M)3. CSP NANP and C-terminus (C-term) IgG models for RTS,S/AS01E vaccinees are provided including IgG concentration (log10 EU mL−1), site and age cohort, with or without
adjusting for baseline (M0) IgG concentrations. Each column is a single multivariable model for each antibody-antigen predictor for the malaria outcome. Separate models were performed for antibody
responses to the two CSP constructs together, and also for the subset of participants who had M0 and M3 matched samples, compared with the full M3 sample analysis
Ref. means the reference variable with which age cohort and site are compared. For example, for the CSP NANP IgG model, Nanoro volunteers had 43× more malaria risk than Bagamoyo, adjusted by age
and antibody concentration
aAdjusted by baseline (M0) IgG concentrations in the same subjects
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immune cells needed for antibody production, less exposed
children at M0 appear able to generate higher responses at M3,
and may beneﬁt most from RTS,S vaccination. This may be
important for the deployment of vaccines in general as prior
parasite clearance may increase vaccine take.
Finally, we explored the effect on vaccination and protection of
other anthropometric variables not analysed thus far. We found
some associations for sex and WAZ, but patterns were not con-
sistent to draw conclusions. The impact of nutrition on vaccine
take merits further investigation in larger studies in case an
intervention could improve effectiveness.
One limitation of our study design was that some baseline sera
were missing, particularly for children from Nanoro, and thus we
could not evaluate the baseline effects at the individual level in the
whole study population. In addition, only 5–17-months-old
children were enrolled at Bagamoyo for the immunology study as
per local protocol. Thus, the ﬁndings related to site could be
confounded by the effect of age. Therefore, further studies are
warranted to assess in more depth the effect of maternally-
transferred antibodies and exposure to other P. falciparum anti-
gens at baseline in relation to M3 peak and long-term main-
tenance of responses.
In conclusion, we generated data on RTS,S/AS01E immuno-
genicity including the C-term of CSP and evaluated antibody
avidity as a quality index essential for immune effector
mechanisms. While our current efforts are devoted to better
deﬁne the type and subclasses of antibodies elicited by RTS,S
vaccination, next steps include the assessment of the functionality
of CSP-speciﬁc IgGs in regards to protection, and the evaluation
of the response kinetics with and without a fourth booster dose at
month 20. The elucidation of the mechanisms underlying RTS,S/
AS01E-induced partial protection is essential for guiding rational
development and deployment of next generation vaccines.
Methods
Study design and subjects. This ancillary immunology study (MAL067) was
nested in the phase 3 RTS,S/AS01E randomised controlled trial (MAL055, Clin-
icalTrials.gov NCT00866619) conducted between 2009 and 2014 in sub-Saharan
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Fig. 4 Effect of CSP antibody avidity on protection against the ﬁrst malaria episode. Kaplan–Meier estimates of time to the ﬁrst clinical malaria episode during
the 12-month follow-up period after the third vaccine dose by the three tertiles (high in grey; medium in blue; low in yellow) of avidity index values at month 3 in
RTS,S/AS01E vaccinees. Only plasma/serum samples which IgG concentrations were above the lower limit of quantiﬁcation (LLOQ) (1.43 EU mL−1 and 2.79
EU mL−1 in NANP (a) and C-terminus [C-term] (b), respectively) were included. The median value for NANP was 0.43 and for C-term 0.11 and the number
of subjects included was n= 691 for NANP and n= 698 for C-term. The median survival time (days), i.e., time at which the survivorship function equals
0.5, are shown next to the plots for each strata with the corresponding 95% conﬁdence intervals. p-values assessing differences in the distribution of
survival time between the two strata were signiﬁcant and have been estimated through the Log-rank test. The number of subjects in each tertile are also
indicated next to the plots, stratiﬁed by age group
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African countries with differing MTIs, including two age cohorts: infants aged
6–12 weeks and children aged 5–17 months at ﬁrst vaccine dose. Volunteers were
vaccinated with either a comparator vaccine or a course of three doses of RTS,S/
AS01E given at study months 0, 1 and 2 (M0, M1, and M2). Serum or plasma was
collected at baseline (M0), and approximately 30 days after the third vaccine dose
(M3). Samples selected were from a subset of 1028 subjects enrolled in 3 out of 7
trial sites participating in the MAL067 study (Kintampo-Ghana, Nanoro-Burkina
Faso, Bagamoyo-Tanzania) and had (i) one-year cumulative incidence high enough
to yield 80% power to detect moderate HRs, (ii) available M3 samples from infants
and children (only children in Bagamoyo as per local protocol), and (iii) varying
MTI (Kintampo moderate-high, Nanoro high-seasonal, Bagamoyo low)16. These
three sites were prioritized because they collectively fulﬁlled the above criteria due
to availability of sufﬁcient numbers and volumes of samples to address the study
objectives. The follow-up by passive case detection (PCD) for clinical malaria
events (fever ≥ 37.5 °C and parasitaemia of any density) was deﬁned for the
12 months starting 14 days after the third vaccine dose. The authors have complied
with all relevant ethical regulations for work with human participants. Written
informed consent was obtained from parents or guardians before the start of the
work. The study protocol was approved by the following relevant institutional or
national Ethics Committees: National Institute for Medical Research, Ifakara
Health Institute (IHI IRB), Tanzania; Ethics Committee of the University and State
of Basel (EKBB), Switzerland; Kintampo Health Research Centre (KHRC) Insti-
tutional Ethics Committee (IEC), and Noguchi Memorial Institute for Medical
Research IRB, Ghana; Institutional EC IRSS and Comite d’Ethique pour la
Recherche en Sante, Burkina Faso; Comitè Ètic d’Investigació Clínica (CEIC, Hos-
pital Clínic, UB), Barcelona, Spain; Research Ethics Committee (REC),
PATH, USA.
CSP antigens. The NANP synthetic peptide used for this study was based on 6
copies of the CSP central repeat sequence (H2NNANPNANPNANPNANPNANP
NANP-C-COOH). The C-term peptide covered 66 amino acids (Ahx-EPSDKHIK
EYLNKIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICK
MEKCS-NH2). Both antigens were sourced by IAVI-HIL from JPT peptide
Technologies (Berlin, Germany). Antigen coating concentration was at 1 μg mL−1.
ELISA assays. IgG titration and avidity assays were performed on the same plate at
IAVI-HIL. Each plate included 6 samples run in two sets of duplicates and 2-step
12-fold serial dilutions (1:50, 1:600, 1:7200). Antigen-speciﬁc standard curves were
implemented using monoclonal antibodies of known concentration (μg mL−1)
(provided by PATH-MVI) speciﬁc to either C-term or NANP. Curves were assayed
in duplicate and 9-step 3-fold serial dilutions starting at 1:200. Positive, negative
and blank controls were assayed in each plate in duplicate. Negative control sera
were obtained from healthy adults living in non-endemic malaria areas (ser-
onegative for CSP). The positivity threshold was deﬁned as the mean+ 2 standard
deviations (SD) of the negative controls (C-term= 2.95 EU mL−1, NANP= 1.78
EU mL−1). Positive controls were a pool of serum samples from RTS,S/AS01-
vaccinated individuals (provided by GSK). Acceptance limits were established prior
to processing samples based on Westgard rules for this positive control.
The indirect ELISA was performed using 1:6000 rabbit anti-human IgG HRP
conjugate (DAKO, Cat No P0214), Sureblue TMB Peroxidase substrate (KPL, Cat
No 52-00-02) and TMB Stop Solution (KPL, Cat No 50-85-06). For the avidity
assay, 1 set of test samples and positive control duplicate wells were incubated for
30min with a chaotropic agent (1M Ammonium thiocyanate, Cat No 12960594,
Fisher Scientiﬁc, UK), whilst the 2nd set of the same samples in duplicate wells on
the plate were incubated with buffer alone. IgG concentration was reported in EU
mL−1 units. The AI was deﬁned as the ratio of interpolated IgG EU mL−1 after
incubating with chaotropic agent divided by the equivalent value from the ELISA
assay without chaotropic agent and multiplied by 100. Standards, negative controls
and blanks were also incubated in buffer and were not treated with chaotropic
agent. For the analysis of AI, we only included samples which anti-CSP IgG
concentrations were above the assay lower limits of quantiﬁcation (LLOQ) provided
by IAVI-HIL (for NANP > 1.43 EU mL−1 and for C-term > 2.79 EU mL−1).
Data analysis. For the descriptive analysis of demographic, clinical, and other
characteristics of subjects between RTS,S/AS01E and comparator vaccinees, cate-
gorical variables were compared through summary statistics, Pearson Chi-square
or Fisher tests, and continuous variables through t-tests or Wilcoxon rank-sum
tests, as appropriate. Graphical and basic exploratory comparisons between vac-
cination groups were done through boxplots and t-tests (Welch corrected).
Associations between antibodies to different antigens were sought through linear
regression and correlation coefﬁcients.
Mixed linear models investigated the effect of the vaccine on the logarithm10-
transformed IgG concentrations for each antigen at M3 and change of
concentrations from M0 to M3 through tests of the corresponding ﬁxed effects (via
combinations of the estimated coefﬁcients), including random intercept and
interaction terms. Additionally, in those models, we considered adjustments for age
cohorts and sites and compared the effect of vaccination on changes of IgG
concentrations from M0 to M3 and on concentrations at M3 across age cohorts
and sites through interaction tests.
The impact of age cohort and site on AI focused on antibodies at M3, only in
RTS,S vaccinees with anti-CSP IgG concentrations greater than the LLOQ. Analysis
was based on correlation, linear regression, and t-tests of log10 AI.
Assessment of the impact of IgG concentration and AI on protection was
primarily based on time to ﬁrst clinical malaria event following the parent trial
main endpoint but, as a secondary endpoint, recurrent malaria events were
analysed. First, Kaplan–Meier time-to-event estimates were compared across
tertile-based categories of antibody responses within vaccination groups through
log-rank tests. In Kaplan–Meier analysis of AI, only samples with IgG
concentration above the LLOQ were included. Second, the effect of each M3
continuous IgG response (CSPs and HBsAg concentrations; AI CSPs) on the
prevention of clinical malaria was assessed by proportional hazard models that
used Anderson and Gill approach when including recurrent events as the
outcome31. Given prior publications suggesting that vaccine efﬁcacy started
declining 3–6 months after vaccination2,32, we were concerned that the protection
conferred by IgGs could wane and be time-varying, assuming that antibodies
mediated the effect of RTS,S/AS01E vaccine efﬁcacy (or were surrogates).
Therefore, the assumption of proportional hazards or constant hazard ratio over
follow-up time was assessed through tests of Schoenfeld residuals. When the
proportional hazards assumption was rejected, the functional representation of the
hazard over time that resulted in the best model ﬁtness was chosen. Optimality of
model ﬁtness was based on Akaike Information Criterion (AIC). In analysis of time
to ﬁrst event, only IgG C-term concentration would require use of time-varying
hazards and, thus, for simplicity of reporting, a constant hazard was forced in. In
analyses of recurrent events, an exponential hazard over time attained the lowest
AIC and, thus, yielded optimal model ﬁtness. Moreover, the HR between age
cohort and recurrent clinical malaria as a function of time categorized at
Table 3 IgG antibody avidities to CSP in relation to risk of clinical malaria
Avidity Avidity+ Concentration
NANP C-term NANP C-term C-term C-term
n subjects 691 700 689 700 694 694
Avidity index IgG M3 0.47 (0.23, 0.94) 0.04 (0.01, 0.22) 0.89 (0.43, 1.83) 0.07 (0.05, 0.90) 0.09 (0.02, 0.70) 0.09 (0.03, 0.31)
Concentration
NANP IgG M3
– – 0.54 (0.44, 0.66) – 0.55 (0.44, 0.70) 0.56 (0.47, 0.67)
Concentration
C-term IgG M3
– – – 0.70 (0.54, 0.91) 1.00 (0.76, 1.34) –
Site
Bagamoyo Ref. Ref. Ref. Ref. Ref Ref.
Kintampo 21.7 (11.7, 40.3) 19.9 (11.2, 35.4) 24.1 (12.9, 44.8) 20.2 (11.4, 35.9) 25.2 (13.6, 46.9) 25.2 (13.6, 47.0)
Nanoro 35.4 (19.1, 65.7) 32.3 (18.2, 55.9) 43.9 (23.5, 82.0) 36.2 (20.3, 64.8) 45.6 (24.3, 85.4) 45.7 (24.4, 85.3)
Age cohort
5–17 months Ref. Ref. Ref. Ref. Ref. Ref.
6–12 weeks 0.92 (0.75, 1.13) 0.81 (0.65, 1.01) 0.60 (0.47, 0.78) 0.76 (0.61, 0.96) 0.53 (0.41, 0.70) 0.54 (0.41, 0.70)
Hazard ratios (95% conﬁdence intervals) for the ﬁrst clinical malaria episode during the 12-month follow-up period after the third vaccine dose in relation to IgG antibody avidity index at month (M)3.
CSP NANP and C-terminus (C-term) IgG models for RTS,S/AS01E vaccines are provided including avidity index, site and age cohort, with or without adjusting for M3 IgG concentrations of the respective
CSP construct and, for C-term, also of the other CSP construct (NANP)
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167–186 days, attained an optimal ﬁt. We chose to adjust models for age
categorized at 180 days or 6 months in all models, for simplicity. We reported
graphically the time-varying hazard ratio for recurrent events of increased antibody
responses.
Concentration of IgG to HBsAg from participants with M3 samples available
(162 [52%] from Kintampo and 277 [62%] from Nanoro) was obtained from the
MAL055 trial database and used to analyse the association between HBsAg
antibody titres and malaria vaccine efﬁcacy in this study. Analyses of the hazard of
recurrent clinical malaria episodes attained optimal ﬁtness per AIC with HBsAg as
a piecewise exponential function split at around 180 follow-up days, depending on
the model. Again, for simplicity and given reports of waning vaccine efﬁcacy at
about 180 days, we chose to standardize models in a split at 180 follow-up days.
In all regression models we considered adjustments for candidate confounders:
sex, WAZ, height-for-age Z-score (HAZ), reported clinical malaria prior to
vaccination, and malaria transmission season, deﬁned according to the rainy
months at the time of M3 sample collection: high for Bagamoyo March–May and
November–December, for Nanoro July–December, and for Kintampo
April–October. Linearity of associations with continuous covariates was evaluated
through penalized splines in generalized additive models (GAM) and no variable
was deemed non-linearly associated. Covariates statistically signiﬁcant to a 0.05
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Fig. 5 Effect of CSP antibody concentration on protection against multiple malaria episodes. Association between continuous anti-CSP IgG responses and the
hazard of recurrent clinical malaria events within a 12-month follow-up period. a One unit increase in IgG NANP protects from clinical malaria and is signiﬁcant
(95% conﬁdence interval [CI] excludes 1) in RTS,S/AS01E vaccinees in the beginning of the follow-up period. As times progresses, increased NANP IgG is less
protective and becomes not signiﬁcant (95% CI includes 1) at approximately 120 post-vaccination days. b The hazard ratio (HR) of C-terminus (C-term) IgG and
recurrent clinical malaria episodes is shown suggesting that increased C-term IgG is signiﬁcantly protective from clinical malaria until day 90 in RTS,S/AS01E
vaccinees. c Increased avidity index (AI) to NANP and, in d increased AI to C-term, is constantly and signiﬁcantly associated with a lower risk of clinical malaria in
RTS,S/AS01E vaccinees. HRs were estimated in a time-varying proportional hazard model with a HR exponentially varying over time (p-value of Schonfeld residual
tests for NANP and C-term IgG was <0.001, thus, rejecting a constant HR). Models for IgG concentrations and AIs also included study sites and age cohort with
the following HRs: NANP IgG—HRKintampo= 25 [14,46], HRNanoro= 31 [17,57], HR612 weeks, <180 days= 2.40 (1.39; 4.14) * [0.99 (0.99; 0.99)]Days; HR612 weeks,
>180 days=0.05 (0.02; 0.11) * [1.01 (1.00; 1.01)]Days; C-term IgG—HRKintampo= 20 [11, 35], HRNanoro= 25 [14, 43], HR612 weeks, <180 days= 3.21 (1.90; 5.41) * [0.99
(0.98; 0.99)]Days, HR612 weeks, >180 days=0.06 (0.03; 0.14) * [1.01 (1.01; 1.01)]Days; NANP AI - HRKintampo= 29 [16, 52], HRNanoro= 37 [21, 68], HR612 weeks= 1.03
[0.91, 1.18]; C-term AI—HRKintampo= 23 [14, 40], HRNanoro= 31 [18, 52], HR612 weeks=0.98 [0.85, 1.13]
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Fig. 6 Effect of HBsAg antibody concentration on protection against malaria episodes. Association between categorized anti-HBsAg IgG responses and
time to the ﬁrst clinical malaria episode (a), and between continuous anti-HBsAg IgG responses and the hazard of ﬁrst (b) and recurrent (c) clinical malaria
events within a 12-month follow-up period. a Kaplan–Meier curves of time to ﬁrst clinical malaria for subjects with anti-HBsAg IgG concentration in the
upper (grey), intermediate (blue) and lower (yellow) tertiles. Median survival time (and 95% conﬁdence interval [CI]) of subjects in each tertile and
sample size stratiﬁed by age group are shown, as well as the p-value of the log-rank test comparing survival time across tertile-based categories. b One unit
increase in continuous anti-HBsAg IgG protects from clinical malaria in analysis unadjusted and adjusted for anti-NANP IgG concentration. c One unit
increase in continuous anti-HBsAg IgG protects from clinical malaria until day 180 and is signiﬁcantly protective of recurrent events of malaria (95% CI
excludes 1) but 180 days after vaccination associations become not statistically signiﬁcant. Comparable results are shown in d when repeating analysis of
recurrent malaria events but adjusting for anti-NANP IgG concentration (p-value of Schonfeld residual tests for analysis of recurrent events unadjusted for
anti-NANP was 0.01 and adjusted for anti-NANP was 0.02, thus, rejecting a constant hazard ratio). All models were adjusted by study site and age cohort
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level or that impacted the coefﬁcient of IgG concentration or AI were retained in
ﬁnal adjusted models. As a result, no covariate other than age and site, were kept in
proportional hazards models. All analyses were stratiﬁed by vaccination group and,
in regression models we considered stratiﬁcation by age cohorts and site when
interaction terms were signiﬁcant to a 0.05 alpha-level. When analysing
immunogenicity and comparing sites, p-values were corrected for multiple testing
through Benjamini-Hochberg and considered signiﬁcant if <0.05. Analyses were
conducted using R v3.4.0 using the functions detailed under code availability
below. Further statistical methodological details are provided in the Supplementary
Methods.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the ﬁndings of this study are available within
the article and its Supplementary Information ﬁles, or are available from the authors
upon reasonable request.
Code availability
Computer codes used to produce results in this article were based on standard R
functions. When comparing means across groups we used t.test and oneway.test. When
estimating correlations, we used the cor function. Tertiles were estimated through the
quantile function. Adjustment of p-values using Benjamin-Hochberg approach was based
on the p.adjust function. All the previous functions were in the standard Stat package of
R. Survival analysis was based on functions found in the survival package: survﬁt,
survdiff, coxph, and cox.zph. Mixed models were ﬁt using function from the Nlme
package: the lme function was used to ﬁt models and the intervals function was used to
estimate 95% CI of these models. Finally, hypothesis test in mixed models involved
testing hypothesis of speciﬁc linear combination of coefﬁcients using the glht function
from the Multicomp package.
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